nanoComposix has expanded its lateral flow rapid test manufacturing capacity with the installation of BioDot reel-to-reel dispensers and laminators. The manufacturing expansion allows for the production of millions of lateral flow assays per month in a new 3000 square foot manufacturing area that includes a low-humidity dry room for lamination and assembly. The manufacturing area is adjacent to the company’s full assay development team and cleanroom for the scaled fabrication of particles and conjugates. With this new expansion, nanoComposix is ready to bring fully designed, ready-to-manufacture diagnostic devices into its facilities to produce at commercial volumes. Offering product transfer support, high-volume manufacturing, and device assembly backed by a team with decades of combined experience, nanoComposix offers a comprehensive solution to rapidly commercialize robust and reliable lateral flow rapid tests.

“Increasing our manufacturing capacity is the next natural step for the company,” nanoComposix CEO & Founder, Dr. Steven Oldenburg said about the development. The company’s lateral flow team is uniquely positioned to solve sensitivity, sample matrix, and quantification challenges with ultra-sensitive nanoparticle probes, covalent binding chemistry, and new advances in quantitative smartphone-based reader technologies. “We now have complete vertical integration under our own roof,” Dr. Oldenburg said. “In addition to supplying gold reagent in bulk and performing large-scale custom conjugations, we now offer end-to-end services to help our customers bring robust, reproducible diagnostic tests to market.”